ORTX Stock Overview
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Orchard Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.36 |
| 52 Week High | US$7.39 |
| 52 Week Low | US$3.60 |
| Beta | 0.92 |
| 1 Month Change | 48.24% |
| 3 Month Change | 40.73% |
| 1 Year Change | 48.96% |
| 3 Year Change | -82.52% |
| 5 Year Change | n/a |
| Change since IPO | -94.74% |
Recent News & Updates
Recent updates
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22FDA signs-off Orchard Therapeutics' gene therapy for rare nerve cell disorder
Nov 19Orchard Therapeutics EPS beats by $0.26, beats on revenue
Nov 03Shareholder Returns
| ORTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.7% | -1.8% | -3.1% |
| 1Y | 49.0% | 10.3% | 15.1% |
Return vs Industry: ORTX exceeded the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: ORTX exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| ORTX volatility | |
|---|---|
| ORTX Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: ORTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ORTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | Bobby Gaspar | https://www.orchard-tx.com |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Orchard Therapeutics plc Fundamentals Summary
| ORTX fundamental statistics | |
|---|---|
| Market Cap | US$170.24m |
| Earnings (TTM) | -US$85.17m |
| Revenue (TTM) | US$21.31m |
8.0x
P/S Ratio-2.0x
P/E RatioIs ORTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORTX income statement (TTM) | |
|---|---|
| Revenue | US$21.31m |
| Cost of Revenue | US$83.09m |
| Gross Profit | -US$61.78m |
| Other Expenses | US$23.39m |
| Earnings | -US$85.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.68 |
| Gross Margin | -289.85% |
| Net Profit Margin | -399.58% |
| Debt/Equity Ratio | 25.6% |
How did ORTX perform over the long term?
See historical performance and comparison